Adherium Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Stock Symbol
  • ADR

Stock Symbol

  • Share Price
  • $0.03
  • (As of Thursday Closing)

Adherium General Information

Description

Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address suboptimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its segment is the Hailie Smartinhaler. Its geographic segments include New Zealand and Australia, Europe, and North America. The majority of its revenue comes from North America.

Contact Information

Website
www.adherium.com
Formerly Known As
Nexus6
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Collins Place Level 25
  • 35 Collins Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03)
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Monitoring Equipment
Stock Exchange
ASX
Vertical(s)
Manufacturing, HealthTech
Corporate Office
  • Collins Place Level 25
  • 35 Collins Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03)

Adherium Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adherium Stock Performance

As of 12-Nov-2026, Adherium’s stock price is $0.03. Its current market cap is $1.88M with 54.9M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.03 $0.04 $0.03 - $0.45 $1.88M 54.9M 48K

Adherium Financials Summary

As of 30-Sep-2026, Adherium has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 3,829 755,928 2,586 6,662
Revenue 1,423 529 551
EBITDA (8,843) (8,046) (6,786)
Net Income (9,594) (8,204) (6,700)
Total Assets 3,141 2,296 6,609
Total Debt 1,653 2,038 62
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Adherium Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adherium‘s full profile, request access.

Request a free trial

Adherium Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that addre
Therapeutic Devices
Melbourne, Australia

Manchester, United Kingdom
 

Amsterdam, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adherium Competitors (8)

One of Adherium’s 8 competitors is Safey, a Formerly Accelerator/Incubator backed company based in Manchester, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Safey Formerly Accelerator/Incubator backed Manchester, United Kingdom
Philips Corporation Amsterdam, Netherlands
Amiko Venture Capital-Backed Milan, Italy
Activ8rlives Accelerator/Incubator Backed St Ives, United Kingdom
AllazoHealth Private Equity-Backed New York, NY
You’re viewing 5 of 8 competitors. Get the full list »

Adherium Patents

  • 125

    Total Documents Applications and Grants

  • Total Patents Families

  • 74

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Adherium Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D1063061-S1 Inhaler usage monitor Active 17-Mar-2022
US-D983962-S1 Compliance monitor for a medicament infuser Active 08-Jul-2021
US-D994113-S1 Compliance monitor for dry powder inhaler Active 05-Nov-2020
US-D991440-S1 Compliance monitor for metered dose inhaler Active 05-Nov-2020
AU-201814618-S A compliance monitor for a medicament inhaler Active 15-Feb-2018
To view Adherium’s complete patent history, request access »

Adherium Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adherium‘s full profile, request access.

Request a free trial

Adherium ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Health Care IT Services

Subindustry

Rank

Percentile

To view Adherium’s complete esg history, request access »

Adherium FAQs

  • When was Adherium founded?

    Adherium was founded in 2001.

  • Where is Adherium headquartered?

    Adherium is headquartered in Melbourne, Australia.

  • What industry is Adherium in?

    Adherium’s primary industry is Therapeutic Devices.

  • Is Adherium a private or public company?

    Adherium is a Public company.

  • What is Adherium’s stock symbol?

    The ticker symbol for Adherium is ADR.

  • What is the current stock price of Adherium?

    As of 12-Nov-2026 the stock price of Adherium is $0.03.

  • What is the current market cap of Adherium?

    The current market capitalization of Adherium is $1.88M.

  • Who are Adherium’s competitors?

    Safey, Philips, Amiko, Activ8rlives, and AllazoHealth are some of the 8 competitors of Adherium.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process